key: cord-0862991-uk4lbym3
authors: Phakathi, Boitumelo; Nietz, Sarah; Cubasch, Herbert; Dickens, Caroline; Dix-Peek, Therese; Joffe, Maureen; Neugut, Alfred I.; Jacobson, Judith; Duarte, Raquel; Ruff, Paul
title: Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV
date: 2021-06-03
journal: Breast
DOI: 10.1016/j.breast.2021.05.014
sha: 78a4ed3e08105d6f5a645d11c69d580fe02ae443
doc_id: 862991
cord_uid: uk4lbym3

PURPOSE: Breast cancer outcomes in sub-Saharan Africa is reported to be poor, with an estimated five-year survival of 50% when compared to almost 90% in high-income countries. Although several studies have looked at the effect of HIV in breast cancer survival, the effect of ARTs has not been well elucidated. METHODS: All females newly diagnosed with invasive breast cancer from May 2015–September 2017 at Charlotte Maxeke Johannesburg Academic and Chris Hani Baragwanath Academic Hospital were enrolled. We analysed overall survival and disease-free survival, comparing HIV positive and negative patients. Kaplan-Meier survival curves were generated with p-values calculated using a log-rank test of equality while hazard ratios and their 95% confidence intervals (CIs) were estimated using Cox regression models. RESULTS: Of 1019 patients enrolled, 22% were HIV positive. The overall survival (95% CI) was 53.5% (50.1–56.7%) with a disease-free survival of 55.8% (52.1–59.3) after 4 years of follow up. HIV infection was associated with worse overall survival (HR (95% CI): 1.50 (1.22–1.85), p < 0.001) and disease-free survival (OR (95% CI):2.63 (1.71–4.03), p < 0.001), especially among those not on ART at the time of breast cancer diagnosis. Advanced stage of the disease and hormone-receptor negative breast cancer subtypes were also associated with poor survival. CONCLUSION: HIV infection was associated with worse overall and disease-free survival. HIV patients on ARTs had favourable overall and disease-free survival and with ARTs now being made accessible to all the outcome of women with HIV and breast cancer is expected to improve.

Breast cancer is the commonest cancer and cause of cancerrelated mortality among women globally [1] . In South Africa, it remains the commonest malignancy among women, accounting for approximately 22% of all malignancies [2] . The lifetime risk (LR) for developing breast cancer in South Africa is estimated to be 1 in 25 women, however, this varies with self-reported race, which is lower than what is reported in the USA (1 in 8 women) [2, 3] .

In 2018, about 38 million people were reported to be living with HIV/AIDS (PLWHIV) worldwide with 68% of them receiving antiretroviral therapy (ART) [4] . In South Africa, 7.52 million PLWHIV were reported with 62% of them being on ARTs in 2018 [4, 5] . Due to the implementation of the universal "test and treat" strategy for all PLWHIV in 2016, the number of patients on ART is expected to rise [6] . So far, the success of the ART program is evidenced by a significant decrease in AIDS-related mortality from 37.2% reported in 2002 to 22 .06% reported in 2018 [5] . The ART regime previously used included, tenofivir disoprostil fumarate & emtricitabine/ lamivudine and efavirenz, but has recently been changed to a new regime: tenofovir, lamivudine and dolutegravir [7, 8] .

Breast cancer survival rates vary globally with high income countries (HICs) having better survivals than low-middle income countries (LMICs). In the United States, the reported 5-year overall survival is 89.9%, compared to 52.3% reported in the sub-Saharan Africa [3, 9] . Some of the contributing factors to the poor overall survival in sub-Saharan Africa include young age at breast cancer diagnosis, advanced clinical stage at presentation, co-morbid disease, black race and aggressive pathological characteristics of breast cancer [9e13] .

Multiple studies were conducted looking at the effect of HIV on breast cancer survival. In a study done in Soweto, South Africa, HIV did not affect the overall survival of breast cancer after 2 years although 42% of patients were lost to follow up [14] . In Botswana, the 2 years overall survival was very low among HIV positive patients than the HIV negative ones (57% vs 73%, P < 0.001) [15] . Similarly, in the USA, a high cancer-specific mortality among HIV positive patients with breast cancer [HR 2.64; 96% CI 1.86e3.73] was reported [16] . A recently published meta-analysis also demonstrated that HIV positive patients had the worst overall survival when compared to HIV negative patients [17] . But none of the published studies specifically looked at the effect of ART use on the survival of breast cancer in HIV positive patients. This study, therefore, aims to describe the effect of HIV infection, duration of HIV positivity, ART use, as well as the duration of ART use on the outcomes of breast cancer in South Africa.

This descriptive study is a sub-study of the South African Breast Cancer and HIV Outcome (SABCHO) study [18] , which was conducted at two public hospitals, Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) Surgical Breast Unit and the Batho Pele Breast Unit of the Chris Hani Baragwanath Academic Hospital (CHBAH). Both these surgical breast units have an estimated HIV prevalence of 22% and diagnose between 250 and 350 new patients with breast cancer every year [18, 19] . The study participants were all consenting women newly diagnosed with breast cancer from 15 May 2015 through 31 September 2017.

An electronic breast cancer database was used to extract the following data: demographics, clinical stage at presentation, comorbidities, level of education and the status of the patient when last seen (alive with no evidence of disease, alive with stable disease, alive with disease progression or dead). Histopathological characteristics (histological type, tumor grade, estrogen (ER) and progesterone receptor (PR) statuses, human epidermal growth factor receptor 2 (HER-2) and Ki67 expression) was obtained from the National Health Laboratory Service (NHLS). An Allred score was used to determine the positivity of both oestrogen and progesterone receptors, with the score of more than 3 regarded as positive [20] . HER2 was regarded positive when the test showed 3þ, with the use of fluorescence in situ hybridization (FISH) reserved for tests with equivocal results(HER2 2þ) [20] . Receptor subtypes were defined as: Luminal A (ER þ, PR þ, HER2 -, Ki 67 < 14%), Luminal B (ER þ, PR þ/À, HER2 -, Ki 67 > 14% or ER þ, PR þ/À, HER-2 þ, any Ki 67), HER2-enriched (ER/PR -, HER2 þ, any Ki 67) and Triple negative (ER/PR/HER2 -, any Ki 67) [21] . The American Joint Committee on Cancer (AJCC) system, 7th edition was used for clinical TNM staging at diagnosis [22] .

Patients with unknown HIV status were counselled and an informed consent for testing was obtained. Post-test counselling was offered to all those newly diagnosed with HIV and blood samples for CD 4 counts and HIV viral load testing were drawn. We recorded the year of HIV diagnosis and when ARTs were initiated, with a cut-off period of one year used to compare those who were on ARTs for a longer period with those who have recently started ARTs (less than a year). Those newly diagnosed with HIV and not on ART were referred to the ART clinic for commencement of ARTs (tenofivir disoprostil fumarate& emtricitabine/lamivudine and efavirenz. For HIV positive patients, CD 4 counts and HIV viral loads were obtained from the NHLS. The viral load below detectable limit was defined as a viral load 50 copies/ml.

Following the completion of prescribed breast cancer treatment, patients were followed up at three-to six-month intervals. If follow-up was missed, patients were called by the research navigators. Completion of chemotherapy and radiation treatment was defined as patients who received the full prescribed number of doses. The first line chemotherapy regime included: Adriamycin (Doxorubicin), Cyclophosphamide and Taxanes (AC-T). At the time of the study, Trastuzumab was not yet available at these two study sites. Overall survival was defined as survival from the date of breast cancer diagnosis to the date of death for any cause while disease free survival was defined as survival from the date of breast cancer diagnosis to the date of disease recurrence or death for any cause. Patients with disease recurrence included all patients with radiologically and histologically confirmed breast cancer recurrence. Patients with stage IV disease at presentation were excluded in the analysis of disease free survival. The site of disease recurrence was sub-classified into loco-regional (ipsilateral chest wall, ipsilateral breast following breast conserving surgery and/or regional lymph nodes) and distant metastases (visceral and nonvisceral sites). The time to and site of disease recurrence were documented. For patients who died, the date of death, as documented in the medical record or as provided by the next-of-kin, was also documented.

Demographic and clinico-pathological data were represented as medians and interquartile ranges for continuous data or as frequencies and percentages for categorical data. Categorical comparisons between HIV positive and HIV negative patients were performed using a c [2] test; age and body mass index (BMI) were compared using a Mann-Whitney test. Patients were censored on the last date they were known to be alive with an administrative censoring date of 31 July 2020 for those still alive at the time of data extraction. Patients censored before the 31 July 2020 were lost to follow up if they could not follow up for more than 9 months and their status could not be ascertained via the 'Verify ID' portal. Kaplan-Meier survival curves were generated assuming noninformative losses to follow-up; p-values were calculated using a log-rank test of equality. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were estimated using Cox regression models. Both unadjusted (crude) HRs and manually adjusted HRs (adjusted for age at diagnosis (continuous), BMI (continuous), stage at diagnosis (2 categories), receptor subtype (4 categories), employment status (2 categories) and education (3 categories)) were calculated. Logistic regression analyses, adjusting for age at diagnosis (2 categories), stage at diagnosis (2 categories) and receptor subtype (4 categories), was used to calculate odds ratios for disease recurrence or death. Data were analysed using STATA v14.2 and the stset suite of commands.

1019 women newly diagnosed with breast cancer were followed up with a median follow up time of 36.9 months (Interquartile range (IQR) 16.8e46.5 months). The HIV status was unknown in 3.33% of patients and 36 (3.5%) were lost to follow up, with a median time to loss to follow up of 16.5 months (IQR 8.3e28.9 months) ( Fig. 1) . Many of our patients (55.8%) presented in stage III & IV of the disease. Basic demographics, clinical and pathological characteristics of all patients are shown in Table 1 .

After 4 years, there were documented 446 deaths (43.8%) with a median (IQR) time to death of 15.7 months (6.9e25.9). The source of deaths was predominantly next of kin (72.0%), followed by the 'Verify ID' portal (16.4%) and hospital records (9.5%). Two percent of patients (n ¼ 11) had no record of the source of death. The overall survival rate (95% CI) was 53.5% (50.1e56.7%) (Fig. 2 ) after 4 years. Age at breast cancer diagnosis did not affect the overall survival (p ¼ 0.326) while HIV positive status, and those not on ART, was associated with poor overall survival (p < 0.001). (Fig. 3 , Table 2 ). Early stage of the disease at diagnosis, hormone receptor positive tumours and a luminal A breast cancer subtype were associated with more favourable outcomes ( Table 2 ).

Out of 730 patients diagnosed with stage I-III, 160 (21.9%) patients had disease recurrence and 207 (28.4%) had died. One hundred and twenty-three stage 1e3 patients had no record of whether they had disease recurrence. The overall median (IQR) time to disease recurrence was 18.9 (12.0e27.1) months with the time being shorter among those who presented with recurrence at distant sites (17.2 (10.1e26.2) months) compared to loco-regional sites (22.4 (14. 5e29.7) months). Majority presented with recurrence at distant sites (55.7%) with lung and pleura combined (35.4%) being the commonest site followed by bone (33.5%), liver (25.3%) and brain (12.0%). Thirty-seven (23.4%) patients presented with disease recurrence loco-regionally while 20.9% had both locoregional and distant sites of recurrence on follow up. One hundred and seven (66.9%) patients with disease recurrence subsequently died.

HIV positive status, an advanced stage at diagnosis, hormone receptor negative tumours and patients who did not completed their prescribed course of chemotherapy had greater odds of disease recurrence or death (Table 3) . Disease free survival (95% CI) was 87.7% (85.3%e89.7%) after 1 year, 72.8% (69.7%e75.7%) after 2 years, 61.5% (58.0%e64.7%) after 3 years and 55.8 (52.1%e59.3%) after 4 years.

Of the 985 patients with known HIV status, 22% were HIV positive with 71.4% of them already diagnosed with HIV before the time of breast cancer diagnosis. Moreover, 60.1% of HIV positive patients were already on ARTs at the time of breast cancer diagnosis. (Table 1 ). HIV positive patients were younger than the HIV negative patients with a median (IQR) age of 44 (39e52), when compared to the HIV negative patients with the median age of 57 years (IQR: 46e67, p < 0.001). Moreover, the HIV positive patients presented more often with an advanced stage of the disease at the time of breast cancer diagnosis than the HIV negative patients (62.3% vs 53.9%, p ¼ 0.028).

Regarding overall survival, HIV infection was strongly associated with a worse overall survival (p < 0.001, Fig. 3 , Table 2 ). Adjusted hazard ratios (95% CI) for overall survival were 1.77 (1.37e2.28) for HIV positive versus HIV negative patients, with age and stage at diagnosis accounting for many of the differences between the unadjusted and adjusted ratios. Among the HIV positive patients, patients who were on ARTs had a better survival when compared to those who were not on ARTs. [HR 0.60 (0.41e0.88), p ¼ 0.008; Fig. 3B ]. Duration of ART use did not however affect overall survival or disease recurrence or death. (Table 4 ). HIV infection increased the odds of disease recurrence or death (29.5% vs 16.4%, OR (95% CI): 2.63 (1.71e4.03), p < 0.001; Table 3 ). Disease free survival by HIV status for those on and not on ART is shown in Fig. 4 . After adjusting for age, stage and receptor subtypes, compared to HIV negative patients, hazard ratios (95% CI) in HIV positive patients on ART were 1.93 (1.44e2.58) and HIV positive patients not on ART they were 2.33 (1.57e3.48).

HIV infection was associated with poorer breast cancer overall survival and greater odds for disease recurrence. A study from Botswana showed that women living with HIV had a lower breast cancer survival than those who were HIV negative [15] . Other studies have also shown that cancer-associated mortality is increased among HIV-positive patients when compared to HIVnegative patients [16, 23, 24] . In the United States, a double-fold increase in mortality among HIV positive patients with breast cancer was reported, with the hazard ratio range between 1.20 (95% CI, 1.14e1.26) and 2.93 (95% CI, 2.08e4.13) [25] . The recently published meta-analysis also revealed a poor overall survival among HIV positive women with breast cancer [17] .

Possible causes for poor breast cancer survival among HIV positive patients remain unclear. One contributory factor is the advanced stage at presentation, which correlates with poorer overall survival [10,11,26e28] . In this study, an advanced disease stage at presentation was strongly associated with a poorer survival compared to an early stage of the disease (p < 0.001), even after adjusting for other known risk factors for poor survival. More of HIV positive patients presented with an advanced stage (Stage III/IV) of the disease at the time of breast cancer diagnosis compared to the HIV negative patients (62.3% vs 53.9%, p ¼ 0.028). Similarly, other studies have shown that PLWHIV are more likely to present with an advanced stage of disease at the time of cancer diagnosis [14, 19, 24] . These findings were, however, contrasted by the findings of a study conducted in Uganda, which showed that HIV positive patients were less likely to present at an advanced stage of disease at the time of cancer diagnosis possibly due to an indirect benefit of being part of the healthcare system for ART [29] .

Another contributory factor is age at breast cancer diagnosis. Women younger than 40 years of age and elderly patients (70e89 years old) are reported to have worse outcomes [10e12]. The mortality rate of breast cancer in young women is reported to be twice the rate of women aged 50e59 [11] . Factors associated with worse prognosis among young women with breast cancer include triple negative breast cancer, luminal B HER-2 enriched and HER-2 enriched breast cancer subtypes and advanced disease stage at the time of diagnosis [10, 11, 30] . Furthermore, it has also been shown that despite adequate treatment, the risk of young women dying of breast cancer remains higher compared to the middle-aged women [31] . However, in this study, there was no association between age and worse overall or disease-free survival. Overall survival and 95% confidence interval for 1016 patients. At 1 year, survival (95% CI) was 83% (81e85%), at 2 years it was 69% (66e72%), at 3 years it was 59% (56e62%) and at 4 years it was 53% (50e57%). Among HIV positive patients, studies have shown improved survival of patients with both AIDS-defining and non-AIDS defining malignancies with the use of ART [32e34]. However, there was no reported association between the use of ART and survival of patients with breast and lung cancers [24] . In this study, we observed an improved breast cancer overall and disease-free survival among HIV positive patients who were on ART compared to those who were not on ART. This could be explained by the effectiveness of ART use in decreasing HIV-associated deaths and not necessarily the breast-cancer specific mortality. Moreover, ART use is also associated with improved immune system and level of CD4 cells lymphocytes, thus improved level of tumour infiltrating lymphocytes which are associated with favourable breast cancer survival [35] . However, the actual effect of ART use on breast cancer specific mortality still needs to be further explored.

Other contributory factors include triple negative breast cancer and HER-2 enriched subtypes [10e13]. A study conducted in Soweto, South Africa showed a 2.5 and 3-fold increase in mortality among patients with HER-2 enriched and triple negative breast cancer subtypes, respectively [14] . Similarly, in this study, triple negative, luminal B and HER-2 enriched breast cancer subtypes were significantly associated with worse breast cancer outcomes.

The overall survival was poor at 55.6% after 4 years of follow-up in this study, an outcome which remains low compared to other geographical regions. In China, an overall survival of 88.64% after 3 years of follow up was reported [12] . In HICs, the overall survival is reported to be higher with the 5-year overall survival of more than 90% [26] . An advanced stage at breast cancer diagnosis is one of the contributing factors for poor survival in LMICs. Studies have shown that more than 75% of patients from several countries in the sub-Saharan Africa have an advanced stage of diseases (stage III/IV) at the time of breast cancer diagnosis [34,36e38] . This is in comparison with patients from HICs, from which less than 20% of breast cancer patients present with an advanced stage of breast cancer [39] . Several other patient-dependent and health care systemdependent factors have been shown to contribute significantly towards late presentation [34, 36, 37] .

The limitations of this study include short follow up of patients and lack of information to determine the breast cancer-specific mortality rate. Routine staging CT scan is not done therefore, it is possible that we might have under-staged our patients. Moreover, we did not adjust for history of AIDS-defining diseases and CD4 þ count at the time of diagnosis, which may play a role in the overall outcome. The severe acute respiratory syndrome coronavirus-2 outbreak disrupted both the clinical care and research not related to COVID-19 globally [40] . In South Africa, the country was put on lockdown from the 26 March 2020, entailing strict movement of individuals except those rendering essential services [41] . During this period, most patients could not come for physical follow-ups mainly due to the increased fear of contracting the virus at the hospital, however telephonic follow-up of these patients was made. Therefore, it is possible that the number of patients with disease recurrence may be underestimated.

HIV infection was associated with poor overall and disease-free survival. Patients on ARTs had favourable overall and disease-free survival and with ARTs now being made accessible to all people living with HIV, the overall survival of women with HIV and breast cancer is expected to improve beyond what it is now.

Ethics clearance for this study was obtained from the Human Research Ethics Committee (Medical) at the University of Witwatersrand (clearance number: M161130 and M150351).

The authors declare no conflicts of interest.

GLO-BOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries

National Cancer Registry. Summary statistics of cancer diagnosed histologically in 2016

HIV/AIDS Data & Statistics. WHO| data & statistics

HIV stats in South Africa mid-year population

patients and differentiated care for stable patients. Department of Health circular

Adult antiretroviral therapy guidelines 2017

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: a population-based registry study

Breast cancer survival by molecular subtype: a population based analysis of cancer registry data

Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort

Factors related to survival rates for breast cancer patients

Breast cancer survival analysis based on immunohistochemistry Subtypes (ER/PR/HER2): a retrospective Cohort Study

Disease free survival by HIV and ART status for 817 patients diagnosed with stage IeIII breast cancer

South Africa: a receptor-defined cohort of women diagnosed from

HIV is associated with decreased breast cancer survival: a prospective, cohort study

Elevated cancer-specific mortality among HIV-infected patients in the United States

Impact of HIV infection on baseline characteristics and survival of women with breast cancer

South African breast cancer and HIV outcomes study: methods and baseline assessment

Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIV

Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast

Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy or early breast cancer

American Joint cancer staging manual

Survival among HIV-infected and HIVuninfected individuals with common non-AIDS-defining cancers

Survival in HIV-infected patients after a cancer diagnosis in the cART era: results of an Italian multicenter study

Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base

Cancer facts & figures 2020

Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital -a closer look into causespecific mortality

Differences in breast cancer survival by molecular subtypes in the United States

Association between HIV infection and cancer stage at presentation at the Uganda Cancer Institute

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression

Breast cancer in young women: poor survival despite intensive treatment

Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies

Non-AIDS-defining cancers among HIV-infected people

Stage at breast cancer diagnosis and distance from diagnostic hospital in a peri-urban setting: a South African public hospital case series of over 1000 women

Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer

Delays in breast cancer presentation and diagnosis at two rural cancer referral centres in Rwanda

Barriers to early-stage presentation of breast cancer among women in Soweto

Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States

SEER Cancer statistics review

Cancer Research: the lessons to learn from COVID-19

South African government: Regulations and guidelines-Coronavirus COVID-19